Gilead Reports Q3 2026 Revenue of $8.3B, Net Income of $2.43B
Revenue rose 6.8% year over year, while net income fell 20.4% to $2.43B and diluted EPS declined 20.2% to $1.94. HIV, Trodelvy and Livdelzi growth partly offset lower Veklury and cell therapy sales.
Gilead Sciences reported third-quarter 2026 revenue of $8.3B, up 6.8% from the prior-year quarter, while net income fell 20.4% to $2.43B and diluted EPS declined 20.2% to $1.94. HIV, Trodelvy and Livdelzi growth partly offset lower Veklury and cell therapy sales.Financial Highlights¹ Reported as “T…